CYTK 241220 165.00P (CYTK241220P165000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

CYTK241220P165000

Watchlist

0.00
0.000.00%

15min DelayTrading Dec 3 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $62 to $120
Moomoo NewsDec 3 08:00 ET · Ratings
Cytokinetics Opens Enrollment for COMET-HF Phase 3 Trial
TipRanksDec 3 07:40 ET
Express News | Cytokinetics Announces Start of Comet-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction
ReutersDec 3 07:30 ET
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), PTC Therapeutics (PTCT) and Vir Biotechnology (VIR)
TipRanksDec 3 05:50 ET · Ratings
Insider Sale: President & CEO of $CYTK (CYTK) Sells 5,000 Shares
Quiver QuantitativeDec 2 19:01 ET
Cytokinetics to Participate in December Investor Conferences
GlobeNewswireDec 2 16:00 ET

Comments

Sean Parker

Nov 19 02:56

$Cytokinetics (CYTK.US)$
Cytokinetics (CYTK) and Bayer have established an exclusive licensing agreement for aficamten in Japan, focusing on treating hypertrophic cardiomyopathy (HCM). The deal includes an upfront payment of €50 million to Cytokinetics, with potential additional earnings of €90 million in milestones through commercial launch (including €20 million near-term) and up to €490 million in commercial milestone payments. The collaboration involves tiered royalties on Japanese sales and ...

Mr Long Term

Aug 13 17:42

Columns Top Calls on Wall Street: Starbucks, Dell, Warner Bros. and More.

Top 5 Upgrades:
Baird upgraded Starbucks $Starbucks (SBUX.US)$ to Outperform from Neutral with a price target of $110, up from $81. The firm sees a more favorable risk/reward on Starbucks shares following the hiring of Brian Niccol as CEO.
Barclays upgraded Dell Technologies $Dell Technologies (DELL.US)$ to Equal Weight from Underweight with an unchanged price target of $97. The firm says much of the artificial intelligence "hype" ...

Rocketier (MAXN)

Jun 11 07:25

$Cytokinetics (CYTK.US)$ cmonnn I know u can up alot further! 🚀

Rocketier (MAXN)

May 29 13:05

$Cytokinetics (CYTK.US)$ will there be potential to gain back 100 after the offering?

zulia3003

May 23 09:02

$Cytokinetics (CYTK.US)$ why drop